scispace - formally typeset
D

Daniel J. Schnell

Researcher at Centers for Disease Control and Prevention

Publications -  12
Citations -  876

Daniel J. Schnell is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Penicillin & Cefoxitin. The author has an hindex of 9, co-authored 12 publications receiving 863 citations.

Papers
More filters
Journal ArticleDOI

Evidence for the effects of HIV antibody counseling and testing on risk behaviors.

TL;DR: It is found that substantial risk reduction among heterosexual couples with one infected partner and among other heterosexuals at increased risk were scanty and mixed, and further studies should specifically address the behavioral consequences of counseling and testing in various settings.
Journal ArticleDOI

National Surveillance of Antimicrobial Resistance in Neisseria gonorrhoeae

TL;DR: The results demonstrate the wide distribution of antimicrobial-resistant N gonorrhoeae and support recent changes in Centers for Disease Control therapy recommendations for gonococcal infections that no longer recommend tetracycline and penicillin as first-line therapies.
Journal ArticleDOI

National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project.

TL;DR: The results demonstrate the wide distribution of antimicrobial-resistant N gonorrhoeae and support recent changes in Centers for Disease Control therapy recommendations for gonococcal infections that no longer recommend tetracycline and penicillin as first-line therapies.
Journal ArticleDOI

Men's disclosure of HIV test results to male primary sex partners.

TL;DR: Most men who did not disclose their test results to their main partner reported being "single" after 6 months, and the relationship remained "as strong as ever" after6 months.
Journal ArticleDOI

National surveillance of antimicrobial resistance in Neisseria gonorrhoeae

TL;DR: The results demonstrate the wide distribution of antimicrobial-resistant N gonorrhoeae and support recent changes in Centers for Disease Control therapy recommendations for gonococcal infections that no longer recommend tetracycline and penicillin as first-line therapies.